Tong Aaron K T, Kao Yung Hsiang, Too Chow Wei, Chin Kenneth F W, Ng David C E, Chow Pierce K H
1 Department of Nuclear Medicine and PET, Singapore General Hospital, Singapore.
2 Department of Nuclear Medicine, The Royal Melbourne Hospital, Melbourne, VIC, Australia.
Br J Radiol. 2016 Jun;89(1062):20150943. doi: 10.1259/bjr.20150943. Epub 2016 Mar 24.
In recent years, yttrium-90 ((90)Y) microsphere radioembolization has been establishing itself as a safe and efficacious treatment for both primary and metastatic liver cancers. This extends to both first-line therapies as well as in the salvage setting. In addition, radioembolization appears efficacious for patients with portal vein thrombosis, which is currently a contraindication for surgery, transplantation and transarterial chemoembolization. This article reviews the efficacy and expanding use of (90)Y microsphere radioembolization with an added emphasis on recent advances in personalized dosimetry and interventional radiology techniques. Directions for future research into combination therapies with radioembolization and expansion into sites other than the liver are also explored.
近年来，钇-90（90Y）微球放射性栓塞已成为治疗原发性和转移性肝癌的一种安全有效的方法。这适用于一线治疗以及挽救性治疗。此外，放射性栓塞对门静脉血栓形成患者似乎有效，而门静脉血栓形成目前是手术、移植和经动脉化疗栓塞的禁忌证。本文综述了90Y微球放射性栓塞的疗效及应用范围的扩大，特别强调了个性化剂量测定和介入放射学技术的最新进展。还探讨了放射性栓塞联合治疗的未来研究方向以及向肝脏以外部位扩展的可能性。
